Search

Displaying results 3941 - 3950 of 10000 in total
  1. Drug

    Midomafetamine

    go.drugbank.com/drugs/DB01454
    IllicitInvestigational

    An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems.

  2. Drug

    Rasburicase

    go.drugbank.com/drugs/DB00049
    ApprovedInvestigational

    Rasburicase is a recombinant urate-oxidase enzyme produced by a genetically modified <i>Saccharomyces cerevisiae</i> strain.

  3. Drug

    Noxytiolin

    go.drugbank.com/drugs/DB13838
    Approved

    Local antibacterial that probably acts by releasing formaldehyde in aqueous solutions.

  4. Drug

    Tarlatamab

    go.drugbank.com/drugs/DB17256
    ApprovedInvestigational

    [L50743] Tarlatamab-dlle was approved by the FDA in May 2024 for use in patients who have failed previous round of platinum-based chemotherapy,[L50743,L50748] becoming the first DLL3-targeting bispecific

  5. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  6. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  7. Drug

    Nerandomilast

    go.drugbank.com/drugs/DB18237
    ApprovedInvestigational

    [L54126] On October 7, 2025, nerandomilast was approved as the first new treatment for idiopathic pulmonary fibrosis in more than a decade.

  8. Drug

    105AD7

    go.drugbank.com/drugs/DB05113
    Investigational

    105AD7 is a human monoclonal antibody that mimics the complement regulatory protein, CD55, overexpressed by many solid tumours including osteosarcoma. 105AD7 induced antitumour inflammatory responses in … metastatic colorectal cancer patients. 105AD7 may be a suitable vaccine for treatment of this disease.

  9. Drug

    Actelion-1

    go.drugbank.com/drugs/DB05367
    Experimental

    Actelion-1 is a tissue-targeting Endothelin Receptor Antagonist that has been discovered by Actelion Pharmaceuticals.

  10. Drug

    gamma-Aminobutyric acid

    go.drugbank.com/drugs/DB02530
    ApprovedInvestigational

    The most common inhibitory neurotransmitter in the central nervous system.

    Synonyms: γ-amino-n-butyric acidMixtures: Theracodophen-Low-90